Italy’s Angelini Said to Explore Catalyst Pharma Acquisition

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals Inc. as it looks at deals to expand its footprint globally, people familiar with the matter said.

Angelini is working with advisers as it studies a possible purchase of US-listed Catalyst, the people said. Discussions are at a preliminary stage, according to the people, who asked not to be identified discussing confidential information.